0001144204-18-049524.txt : 20180914
0001144204-18-049524.hdr.sgml : 20180914
20180914163139
ACCESSION NUMBER: 0001144204-18-049524
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180913
FILED AS OF DATE: 20180914
DATE AS OF CHANGE: 20180914
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Maimon Yossi
CENTRAL INDEX KEY: 0001385115
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33357
FILM NUMBER: 181071498
MAIL ADDRESS:
STREET 1: C/O PROTALIX BIOTHERAPEUTICS, INC.
STREET 2: 2 SNUNIT ST, SCIENCE PARK, POB 455
CITY: CARMIEL
STATE: L3
ZIP: 20100
FORMER NAME:
FORMER CONFORMED NAME: Yossi Maimon
DATE OF NAME CHANGE: 20070104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc.
CENTRAL INDEX KEY: 0001006281
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 650643773
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 SNUNIT ST
STREET 2: SCIENCE PARK, POB 455
CITY: CARMIEL
STATE: L3
ZIP: 20100
BUSINESS PHONE: 972-4-988-9488
MAIL ADDRESS:
STREET 1: 2 SNUNIT ST
STREET 2: SCIENCE PARK, POB 455
CITY: CARMIEL
STATE: L3
ZIP: 20100
FORMER COMPANY:
FORMER CONFORMED NAME: ORTHODONTIX INC
DATE OF NAME CHANGE: 19980422
FORMER COMPANY:
FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP
DATE OF NAME CHANGE: 19960124
4
1
tv502884_4.xml
OWNERSHIP DOCUMENT
X0306
4
2018-09-13
0
0001006281
Protalix BioTherapeutics, Inc.
PLX
0001385115
Maimon Yossi
C/O PROTALIX BIOTHERAPEUTICS, INC.
2 SNUNIT STREET, SCIENCE PARK, POB 455
CARMIEL
L3
20100
ISRAEL
0
1
0
0
VP, Chief Financial Officer
Stock Options (Right to Buy)
0.56
2018-09-13
4
A
0
700000
0
A
2028-09-13
Common Stock
700000
700000
D
The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.
Does not include (i) options to purchase 130,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (ii) options to purchase 250,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025.
/s/ Yossi Maimon
2018-09-14